HACKENSACK, N.J.--(BUSINESS WIRE)--June 27, 2006--Amorcyte Inc (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, announced today that it has signed an exclusive agreement for the development and manufacturing of Amorcyte's lead product, AMR-001, with Progenitor Cell Therapy, LLC (PCT), a leading full service cell therapy development and contract manufacturing company.
